Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...
Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year.
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback